
NASDAQHealthcareBiotechnology
Latest quote
$7.05
−$0.07 · -0.98%
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Previous close
$7.05
−$0.07 · -0.98%
Regular session · ET · Market data may be delayed.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Day range
Current $7.05
52-week range
Current $7.05
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
72
Bullish
Risk
39
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Day range
Current $7.05
52-week range
Current $7.05
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV18.37M0.06%30.51B USD0.25%$114.4-1.82%
Vanguard Morningstar Total Stock Market ETFVTI11.05M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM8.53M0.01%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF4.76M0.01%30.2B USD0.05%$211.44-3.21%
Dimensional - US Targeted Value ETFDFAT2.93M0.01%29.57B USD0.31%$65.61-1.74%
Vanguard Russell 2000 ETFVTWO2.72M0.02%16.8B USD0.06%$103.76-2.76%
Dimensional - US Small Cap ETFDFAS2.71M0.01%31.24B USD0.30%$74.24-2.48%
iShares Russell 2000 Value ETFIWN2.54M0.02%13.05B USD0.24%$198.84-2.08%
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Dimensional - US Targeted Value ETFDFAT
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
iShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.